[
  {
    "ts": null,
    "headline": "TD Cowen Maintains its Buy Rating and $100 PT for DexCom, Inc. (DXCM)",
    "summary": "With significant upside potential, DexCom, Inc. (NASDAQ:DXCM) secures a spot on our list of the 13 Best Quality Stocks to Buy According to Hedge Funds. On September 25, 2025, given that previous technical problems with the company’s G7 continuous glucose monitoring (CGM) technology had been fixed, TD Cowen kept its buy rating and $100 price […]",
    "url": "https://finnhub.io/api/news?id=6ccff78d5e19c462fec4aba856a1e3a57fce4bf9a1e8bd3b6548db2d3a1e13a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759362036,
      "headline": "TD Cowen Maintains its Buy Rating and $100 PT for DexCom, Inc. (DXCM)",
      "id": 136952616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "With significant upside potential, DexCom, Inc. (NASDAQ:DXCM) secures a spot on our list of the 13 Best Quality Stocks to Buy According to Hedge Funds. On September 25, 2025, given that previous technical problems with the company’s G7 continuous glucose monitoring (CGM) technology had been fixed, TD Cowen kept its buy rating and $100 price […]",
      "url": "https://finnhub.io/api/news?id=6ccff78d5e19c462fec4aba856a1e3a57fce4bf9a1e8bd3b6548db2d3a1e13a4"
    }
  },
  {
    "ts": null,
    "headline": "DexCom, Inc. (DXCM) Showcases Next-Gen CGM Features at EASD 2025",
    "summary": "We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them. DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems, continues to advance diabetes care with its flagship G6 and G7 devices, which provide real-time glucose tracking and data sharing. […]",
    "url": "https://finnhub.io/api/news?id=f0e3c74a957f6973a3b8332e30c248fc265d9b69ac58c5e658283bce8b0a3fc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759341345,
      "headline": "DexCom, Inc. (DXCM) Showcases Next-Gen CGM Features at EASD 2025",
      "id": 136952617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them. DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems, continues to advance diabetes care with its flagship G6 and G7 devices, which provide real-time glucose tracking and data sharing. […]",
      "url": "https://finnhub.io/api/news?id=f0e3c74a957f6973a3b8332e30c248fc265d9b69ac58c5e658283bce8b0a3fc3"
    }
  },
  {
    "ts": null,
    "headline": "United States Continuous Glucose Monitoring (CGM) Market Forecast 2025-2033: Focus on California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, Washington, New Jersey",
    "summary": "The United States Continuous Glucose Monitoring (CGM) Market is projected to surge from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033, growing at a CAGR of 8.36% from 2025-2033. Key growth drivers include the rising prevalence of diabetes, technological advancements, enhanced insurance coverage, and increased awareness. Major players like Dexcom, Abbott, and Medtronic lead the market with user-friendly, accurate devices. The integration of CGMs is pivotal for proactive diabetes management",
    "url": "https://finnhub.io/api/news?id=778ea0f24c755b343887fce862fc24e367ddb8c6783d818bf68b842abe5b1563",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759319040,
      "headline": "United States Continuous Glucose Monitoring (CGM) Market Forecast 2025-2033: Focus on California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, Washington, New Jersey",
      "id": 136944618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "The United States Continuous Glucose Monitoring (CGM) Market is projected to surge from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033, growing at a CAGR of 8.36% from 2025-2033. Key growth drivers include the rising prevalence of diabetes, technological advancements, enhanced insurance coverage, and increased awareness. Major players like Dexcom, Abbott, and Medtronic lead the market with user-friendly, accurate devices. The integration of CGMs is pivotal for proactive diabetes management",
      "url": "https://finnhub.io/api/news?id=778ea0f24c755b343887fce862fc24e367ddb8c6783d818bf68b842abe5b1563"
    }
  }
]